Ampreloxetine’s Section 3 failure in a number of system atrophy is the third disappointing medical trial end result for the Theravance Biopharma drug. The biotech will now wind down all R&D and discover choices that might embrace the sale of the corporate.
The publish Theravance Drug Fails One other Pivotal Take a look at, This Time Sparking Restructuring That Ends R&D appeared first on MedCity Information.
